Stephen J. Forman - 30 Sep 2024 Form 4 Insider Report for LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT)

Role
Director
Signature
/s/ Stephen Forman
Issuer symbol
LIXT
Transactions as of
30 Sep 2024
Net transactions value
$0
Form type
4
Filing time
29 Oct 2024, 17:42:33 UTC
Previous filing
02 Jul 2024
Next filing
22 Jan 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LIXT Options to Purchase Common Stock Award $0 +3,858 $0.000000 3,858 30 Sep 2024 Common 3,858 $1.30 Direct F1
holding LIXT Options to Purchase Common Stock 10,000 30 Sep 2024 Common 10,000 $2.37 Direct
holding LIXT Options to Purchase Common Stock 3,018 30 Sep 2024 Common 3,018 $2.37 Direct
holding LIXT Options to Purchase Common Stock 10,000 30 Sep 2024 Common 10,000 $5.88 Direct
holding LIXT Options to Purchase Common Stock 10,000 30 Sep 2024 Common 10,000 $7.45 Direct
holding LIXT Options to Purchase Common Stock 10,000 30 Sep 2024 Common 10,000 $30.30 Direct
holding LIXT Options to Purchase Common Stock 5,000 30 Sep 2024 Common 5,000 $32.10 Direct
holding LIXT Warrants to Purchase Common Stock 2,105 30 Sep 2024 Common 2,105 $57.00 By Stephen Forman Living Trust
holding LIXT Options to Purchase Common Stock 833 30 Sep 2024 Common 833 $9.00 Direct
holding LIXT Options to Purchase Common Stock 833 30 Sep 2024 Common 833 $66.00 Direct
holding LIXT Warrants to Purchase Common Stock 1,667 30 Sep 2024 Common 1,667 $60.00 By Stephen Forman Living Trust
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Effective September 30, 2024, the reporting person was granted stock options to purchase an aggregate of 3,858 shares vesting immediately. The grant was in lieu of the quarterly cash compensation due to the reporting person under the Board Compensation Plan.